Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study
Figure 4
Treatment with RTL1000 did not induce immunosuppression. PBMC collected prior to and 14 and 28 d after infusion of drug from two subjects receiving 60 mg drug, three subjects receiving 200 mg drug and one placebo subject was evaluated for levels of secreted IL-6 (a) and MIP-1α (b) in supernatants collected 48 h after stimulation with anti-CD3 mAb or in unstimulated Control cultures. No significant changes were observed at either postinfusion time point.
